
|Videos|November 14, 2022
A Historical Perspective on First-Line Treatment of NSCLC and Recent Advances in Immunotherapy
Author(s)Joshua K. Sabari, MD
In the first installment of this series, Joshua Sabari, MD, provides an overview on the use of chemotherapy for first-line treatment of NSCLC, and discusses how the more recent availability of PD-1/PD-L1– and CTLA-4–targeted immunotherapy is changing the field.
Episodes in this series








































